Trentin

Quick links to important sections

Trentin

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trentin

Quick Facts

Property Description
Active ingredient Tretinoin (all-trans retinoic acid, ATRA)
Form Topical formulations (Cream, Gel, Solution); Oral Capsules
Pharmacological class Retinoid (First-generation)
General Purpose Normalization of skin cell growth and shedding
Origin Synthetic analogue and natural metabolite of Vitamin A

What is Trentin? Definition, Substance, and Class

Trentin is a medicinal product containing the single active ingredient Tretinoin, which is the International Nonproprietary Name (INN) for all-trans retinoic acid (ATRA). Tretinoin is classified as a powerful first-generation Retinoid, a pharmacological class encompassing compounds structurally and functionally related to Vitamin A. This substance is significant because it functions as both a naturally occurring metabolite of Vitamin A and is produced synthetically for pharmaceutical purposes, distinguishing it as a prescription-only medicine. Its authoritative standing is confirmed by its inclusion on the World Health Organization's Model List of Essential Medicines.

Composition, Form, and General Purpose

The active component, Tretinoin, is most frequently delivered as a single-ingredient product in various topical formulations, including Creams, Gels, and Solutions, intended for administration directly to the skin. The choice of form is a key differentiating factor, with the Gel formulation often preferred for oilier skin due to its lighter base compared to emulsions. The general purpose of this retinoid is to act as a potent keratolytic and comedolytic agent. It is clinically recognized for its ability to regulate the critical growth and differentiation of epithelial cells, which is the foundational action required to manage conditions involving skin texture and blocked pores. This mechanism, supported by extensive pharmacological studies, helps maintain clear pores and promotes a consistent and healthy rate of skin renewal.

Regulatory References

  1. NIH StatPearls
  2. World Health Organization's Model List of Essential Medicines

What side effects are possible with Trentin?

Possible Side Effects and Safety Information

The officially documented safety profile for Trentin (Tretinoin) is structured according to its administration route, distinguishing between local effects from topical use and serious systemic risks associated with the oral formulation.

Adverse Reactions: Topical Application

Adverse reactions to the topical formulation are primarily classified under Skin and Subcutaneous Tissue Disorders. These are often localized and tend to be most prominent during the first two weeks of treatment. Reactions classified as Very Common (ge10%) include skin peeling, dryness, erythema (redness), and a burning sensation. Common reactions (1% to 10%) include pruritus, dermatitis, and skin pain. The labeling also notes increased sensitivity to environmental factors such as sunlight, wind, or cold weather.

Adverse Reactions: Oral Application

The oral formulation, used in specialized systemic support, presents a safety profile characterized by widespread systemic effects. Very Common reactions often involve Constitutional Symptoms (e.g., headache, fever, fatigue) and Gastrointestinal Disorders (e.g., nausea, vomiting, GI hemorrhage). Adverse reactions are also documented across the Nervous System and Hematologic System.

Serious Safety Considerations

The regulatory labeling for oral Tretinoin identifies specific serious adverse reactions. These include Differentiation Syndrome (historically RA-APL Syndrome), which occurs most commonly during the first month of therapy. Other documented serious risks include Pseudotumor Cerebri (Intracranial Hypertension) and serious Thrombotic Events.

Furthermore, Tretinoin is defined by a significant teratogenic risk. The oral formulation carries an absolute contraindication during pregnancy, and topical use is generally not recommended due to safety concerns.

Overdose and Emergency Response

Overdose manifestations for Tretinoin (Trentin) are officially classified based on the route of exposure. Excessive topical application is documented to cause severe local irritation, including marked erythema, peeling, pruritus, and blistering. If this severe irritation occurs, the regulator-mandated action is immediate interruption of use.

Accidental oral ingestion, regardless of the formulation, may lead to systemic toxicity presenting as symptoms of acute Hypervitaminosis A, such as severe headache, vomiting, dizziness, and loss of coordination. For accidental ingestion, the official labeling specifies that immediate medical attention must be sought.

Severe systemic overdose carries the documented risk of life-threatening outcomes, including Differentiation Syndrome (RA-APL syndrome) and Intracranial Hypertension (pseudotumour cerebri). Differentiation Syndrome involves acute respiratory distress, pleural effusions, and potential multi-organ failure. For life-threatening symptoms, such as collapse or sudden breathing difficulty, emergency services (e.g., 911) or a Poison Control center must be contacted immediately.

Management is symptomatic and supportive; for Differentiation Syndrome, the immediate administration of high-dose corticosteroids is required, alongside continuous hemodynamic monitoring. Regulatory documents also note that Intracranial Hypertension has a higher incidence in pediatric patients receiving systemic therapy.

Therapeutic Uses of Trentin

What Trentin Treats: Main Uses and Benefits

Trentin (Tretinoin) is commonly used to help with therapeutic benefits across two distinct clinical domains, offering both management for conditions presenting with systemic or localized discomfort and intervention for a specialized, critical condition. The scope of uses for Tretinoin is clinically recognized for its role in addressing specific dermatologic and hematologic needs.

Management of Dermatologic Symptoms

This topical application is used to address the symptomatic clusters of Acne Vulgaris and signs of photoaging. For acne, the primary benefit is in reducing the overall burden of active lesions, including both inflammatory types and non-inflammatory lesions. For sun-damaged skin, it assists with mitigating the visible manifestations of chronic sun exposure, such as fine facial wrinkles, tactile skin roughness, and associated mottled hyperpigmentation. This application provides support that contributes to improved day-to-day comfort and stability in skin appearance.

Specialized Systemic Support

The oral formulation of Trentin is relevant in highly specialized clinical settings marked by the aggressive blood cancer, Acute Promyelocytic Leukemia (APL). This systemic use is applied during the acute phase for managing the induction of disease remission. This therapeutic support is considered relevant for managing this hematologic condition, helping patients cope more steadily with a difficult, critical episode. The core indications are Acne Vulgaris, photoaging symptoms, and Acute Promyelocytic Leukemia (APL).


Quick Fact: Therapeutic Domains
Symptom Clusters Addressed Helps address groups of symptoms related to inflammatory or irritative skin states and manages symptoms linked to organ-specific functional stress (APL).
Clinical Contexts of Use Applied across domains where additional symptomatic support is needed in contexts involving inflammatory processes, and in clinical settings that involve acute or unstable symptom patterns.

Regulatory References

  1. NIH MedlinePlus Overview

Eligibility and Restrictions for Use

Who can and cannot use Trentin?

Eligibility for Tretinoin (Trentin), in both its oral and topical forms, is strictly regulated and determined by specific physiological and clinical statuses documented in official government labeling.

Eligibility Status Population/Condition Regulatory Classification
Use is Contraindicated Pregnancy or Women Planning Pregnancy Absolute Exclusion (due to severe teratogenic risk)
Use is Contraindicated Known Hypersensitivity to Tretinoin or Excipients Absolute Exclusion
Use is Contraindicated Breastfeeding Mothers Absolute Exclusion
Use Requires Caution Hepatic and/or Renal Impairment Restricted Use (Caution/Dose Reduction May Be Required)
Use Requires Caution Topical: Eczematous Skin Restricted Use (Risk of Severe Irritation)

Official regulatory documents define the population eligible for this medicine by the absolute exclusion of women who are pregnant or may become pregnant, classifying this as a formal contraindication. Women of childbearing potential receiving the oral formulation must adhere to a mandatory Pregnancy Prevention Programme. Additionally, the medicine is contraindicated for any patient with a documented hypersensitivity to its components. Age restrictions apply to the topical formulations, which are generally not recommended for use in children under 12 years of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The Tretinoin (Trentin) interaction profile is defined by its dual formulation—oral (systemic) and topical (local)—as documented in authoritative regulatory sources.

Systemic (Oral) Interactions

Interaction Type Interacting Substance/Class Official Restriction / Outcome
Contraindicated Tetracyclines (e.g., Minocycline) Avoid due to additive risk of increased intracranial pressure
Pharmacokinetic Strong CYP3A Inhibitors Increases Tretinoin plasma concentration; avoidance required
Pharmacodynamic Anti-fibrinolytic Agents Avoid concomitant use due to increased risk of thrombosis
Substance Vitamin A Supplements Prohibited due to risk of aggravating hypervitaminosis A symptoms

Co-administration of the oral formulation with Strong CYP3A Inducers is also avoided because of the potential for reduced Tretinoin exposure. The regulatory profile establishes clear constraints based on metabolic pathways and severe adverse event risk.

Local (Topical) Interactions

Topical Tretinoin requires caution when combined with certain products due to the risk of additive local effects, rather than systemic exposure modification.

Interaction Type Interacting Substance/Class Official Restriction / Outcome
Pharmacodynamic Photosensitizing Drugs May lead to augmented phototoxicity
Local Irritation Topical Acne Preparations (e.g., Benzoyl Peroxide) Use with caution; may require skin to “rest” before use
Substance Products with High Alcohol Content Caution advised due to potential for additive drying and irritation

Mechanism of Action

How Trentin Works: Molecular Mechanism of Action

Gene Regulation via Nuclear Receptor Agonism

Tretinoin acts as a high-affinity agonist for the Retinoic Acid Receptors ( RARs), particularly RARgamma, the predominant isoform in the epidermis. This molecular interaction activates the receptor, forming a complex that binds to specific DNA sequences ( RAREs) to modulate (activate or suppress) the transcription of numerous target genes. This fundamental change in gene expression dictates the cell's future differentiation and proliferation patterns, initiating all downstream physiological effects.

Regulating Follicular Cell Turnover and Shedding

The regulated gene expression directly affects the follicular keratinization pathway. By suppressing genes that promote epithelial cell cohesiveness and simultaneously accelerating the cell replacement rate, Tretinoin regulates cell shedding within the follicular structure. This mechanism leads to the reduction of cellular debris cohesiveness, which supports the expulsion of contents from the follicular structure.

Dual Action: Anti-inflammation and Dermal Matrix Alteration

Tretinoin's mechanism includes a concurrent anti-inflammatory action achieved through the transcriptional repression of pro-inflammatory factors like AP-1. Furthermore, it targets the dermal matrix components by stimulating fibroblasts to synthesize structural proteins like procollagen, while also inhibiting the enzymes that break down existing dermal components. This dual action alters tissue structure and reduces the presence of pro-inflammatory mediators.

Dosage and Administration Information

How to Use Trentin: Official Administration Guidelines

Trentin (Tretinoin) administration is strictly defined, prescribing specific protocols for its two approved routes of use: topical and oral.


Administration Scope

Category Instruction
Route of administration Oral (Capsules, for systemic use) and Topical (Cream, Gel, Solution, or Lotion, for localized skin application).
Dosing schedule (Adults) Oral (Systemic): 45 mg/m^2 per day, calculated based on body surface area. Topical (Localized): A pea-sized amount or a thin layer is applied to the entire affected area.
Frequency pattern Topical: Applied once daily, typically in the evening. Oral: The total daily dose is administered in two evenly divided doses per day.
Conditional Intake Oral: Capsules must be taken with a meal and must be swallowed whole (not chewed or opened). Topical: Applied to clean, completely dry skin, often requiring a 20 to 30 minute waiting period post-cleansing.
Age-group rules Topical: Approved for use in patients 12 years of age and older. Oral: The mg/m^2 dosing principle applies to pediatric patients for systemic induction therapy.

Official Procedural Structure

The protocols define the entire course of use based on the specific formulation. For systemic use, the dose must be calculated precisely, divided into two parts, and consistently taken with food. For topical use, the procedural focus is on the application technique, which mandates using a minimal volume, applying to fully dry skin, and strictly avoiding contact with mucous membranes or the eyes.

Course Duration: Topical use typically requires more than seven weeks of continuous application to observe effects, while oral systemic administration continues until a specific remission endpoint is documented, followed by regulated discontinuation, usually within a maximum of 90 days.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Substance A and Substance B for Osteoarthritis

Research has explored whether the substance influences the quality of life and affects pain and inflammation associated with osteoarthritis (OA). The studies reported findings regarding the combination as assessed and its profile in trials.

The research conducted included randomized, controlled trials (RCTs) and observational studies across Europe and Asia. The studies focused on participants with diagnosed mild to moderate OA of the knee and hip. The primary outcome measures typically involved self-reported pain scores (e.g., VAS, WOMAC) and objective measures of joint function.

Studies evaluated whether the substance influenced pain and affected joint function in participants with mild to moderate OA. The combination was examined in comparison to placebo and other monotherapies in terms of observed findings.

Reported Findings

  • Pain and Inflammation: Several trials reported differences in mean pain scores between the group receiving the combination and the placebo group.
  • Joint Function: Measurements of joint mobility and stiffness reported differences in the treatment group compared to baseline.
  • Trial reports indicated that changes were recorded in some participants after 4-6 weeks of treatment. The studies typically assessed participant outcomes over a period of at least 3 months.

Tolerability Profile

  • The combination's tolerability was assessed across the studies.
  • The most frequently reported adverse events included gastrointestinal disturbances, such as nausea or indigestion, which were generally comparable to the rates reported for the placebo group.
  • New or severe events were not identified in the aggregate analysis of the trials.

Limitations and Gaps

While the available evidence reports outcomes for this combination, research remains limited concerning its long-term effects (beyond two years). It is not yet established whether the substance influences the progression of structural joint damage in OA. Furthermore, findings were mixed when assessing the combination's use in severe-stage OA, indicating a need for more focused research in that specific patient group.

Key Studies & References Managing Knee Osteoarthritis: Systemic Pharmacotherapy and Intra-Articular Treatments (Review)

Frequently Asked Questions (FAQ)

Common questions about Trentin (FAQ)


Q: How long does it usually take to feel the effects of Trentin?

Studies and official information indicate that the time to observe effects depends on the formulation. For topical use, maximum expected results to be observed are typically after more than six weeks of continuous use. For the oral formulation, the treatment is used until an official remission endpoint is documented.


Q: Is it normal to feel [general side effect] when starting Trentin?

Official product information classifies certain side effects as Very Common, particularly when starting treatment. For the topical form, localized reactions like redness, peeling, and dryness are most prominent during the first two weeks. For the oral form, systemic symptoms such as fatigue or headache are also commonly reported.


Q: Can Trentin affect my ability to drive or operate machinery?

Regulatory documents mention that the oral formulation may cause side effects such as dizziness or severe headache. Regulatory information suggests caution should be exercised before driving a car or operating heavy machinery until the effect of the medicine is known.


Q: Are there any common foods or drinks that should be avoided while taking Trentin?

Official documents specify the oral capsules are to be taken with a meal for proper absorption. Regulatory documents also explicitly prohibit taking Vitamin A supplements concurrently. This is due to the potential risk of increasing symptoms associated with having too much Vitamin A in the body (hypervitaminosis A).


Q: Is Trentin safe to use for older adults?

While older age is not an absolute exclusion (contraindication), official documents indicate that dedicated safety studies may not have specifically established a distinct safety profile for the geriatric population.


Q: Is there a generic version of Trentin available?

Yes, the active ingredient, Tretinoin, is available in various generic formulations. This includes creams, gels, and oral capsules that have been reviewed and approved by regulatory bodies.


Q: What does the term 'contraindication' mean in relation to Trentin?

A contraindication is a factor or condition that legally prohibits the use of a drug because the risks far outweigh any potential benefit. Official product information lists a contraindication for individuals who are pregnant or have a known hypersensitivity (allergy) to the drug.


Q: How long do most people typically need to take Trentin?

The typical course varies depending on the medical need and the formulation prescribed. Topical treatment often takes more than six weeks for results to show. The duration of the oral systemic treatment is determined by a doctor based on documented remission.


Q: Is Trentin a habit-forming or addictive medicine?

According to official safety classifications, Tretinoin is a retinoid and is not listed as a controlled substance. This classification indicates that regulatory bodies do not classify it as having a significant risk for abuse or dependence.


Q: What is the known 'ceiling' effect for Trentin (where higher doses don't help more)?

For the topical formulation, regulatory documents explicitly state that excessive use does not enhance therapeutic effects. Instead, using too much may lead to marked inflammatory skin reactions like excessive redness and peeling.


Q: Is it safe to stop taking Trentin suddenly?

Official documents define the oral systemic course as highly regulated, where discontinuation must follow a specific remission endpoint. Official documents do not provide general instructions regarding sudden cessation of the topical formulation.


Q: What if I experience side effects that are not listed in the official document?

Regulatory documents direct patients to report suspected adverse reactions to the drug manufacturer or the national regulatory authority. This includes any experience that is not already described in the official product labeling.


Q: How soon after stopping Trentin does it leave the system?

The rate at which the drug leaves the body is described by pharmacokinetics. The oral formulation has a relatively fast clearance rate, with a reported terminal elimination half-life of 0.5 to 2 hours following the initial dose.


Q: Are there any restrictions on activity while using Trentin?

Patients using the topical formulation are advised to take precautions against environmental factors. This includes minimizing unprotected exposure to sunlight and avoiding exposure to weather extremes like strong wind or cold, as this can increase skin irritation.


Q: Does Trentin interact with common over-the-counter pain relievers?

Official information suggests that a significant drug interaction is not typically expected between the oral formulation of Tretinoin and non-prescription pain relievers like acetaminophen. However, official guidelines always recommend caution when combining any medications.


Q: What are the signs that Trentin might not be working as expected?

For the topical formulation, official warnings state that skin improvement should be noticeable within 8 to 12 weeks. If the treated condition does not improve within this timeframe, the regulatory warning implies that re-evaluation by a healthcare professional is appropriate.


Q: What were the main outcomes studied in the clinical trials for Trentin?

Clinical trials for the topical formulation typically focused on its ability to improve the treated condition. Primary outcomes measured usually included the reduction in the number of lesions and improvement in the overall severity of the condition.


Q: Can Trentin be taken while fasting?

No. Official documents specify the oral capsules are to be taken with a meal. This is a specific administration condition outlined in regulatory documents to ensure the medication is absorbed correctly by the body.


Q: What happens if I accidentally take two doses close together?

For topical use, regulatory documents advise patients not to apply two doses at one time to make up for a missed dose. In the event of an acute oral overdose, although rare, symptoms may include headache or dizziness, and medical attention may be appropriate.


Q: Is it possible to be allergic to Trentin?

Yes, it is possible. Regulatory documents list a known hypersensitivity (allergy) to Tretinoin or any of its inactive ingredients as an absolute contraindication. This means the medicine is excluded for use by anyone with such an allergy.


Q: Are there any major differences between the dosage forms of Trentin?

Yes, there are differences in the bases used for the topical forms. Creams are typically better for drier skin types, while Gels often contain alcohol and are preferred for oilier skin, though they may cause more localized drying or irritation.

How should Trentin be stored and disposed of?

This medication must be stored according to specific regulatory requirements to maintain its stability and effectiveness.

Official Storage Requirements

Storage Factor Requirement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep the container tightly closed and protect from direct light and moisture. Protect from freezing and excessive heat (do not store above 49 C / 120 F).
Handling Note Some gel formulations are flammable; avoid fire, flame, or smoking during use.
Safety Keep this medication, and all drugs, out of the sight and reach of children.

Disposal

To dispose of unused or expired Trentin, consult a healthcare professional, pharmacist, or local waste disposal company. Do not keep outdated medication. Dispose of the product and its packaging according to regional and national regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trentin found in:

A-Z Index: